AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Silo Pharma, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG002D1DZR7
1.18▲ 0.00 (0.00%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
1.18
Day's Range
1.17 – 1.20
52-Week Range
0.22 – 7.95
Volume
6,574
Avg Volume
53.5K
Share Statistics
Shares Outstanding
Employees
3
Exchange
XNAS
Listed
2012-01-05
Share count as of August 13, 2026

Silo Pharma, Inc. Common Stock (SILO) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Silo Pharma, Inc. Common Stock (SILO)
What is Silo Pharma, Inc. Common Stock's Market Cap?
Silo Pharma, Inc. Common Stock's Market Cap is $1.9M, based on as-reported figures from SEC (XBRL) filings.
What is Silo Pharma, Inc. Common Stock's Enterprise Value?
Silo Pharma, Inc. Common Stock's Enterprise Value is -$4.2M, based on as-reported figures from SEC (XBRL) filings.
What is Silo Pharma, Inc. Common Stock's Price / Sales?
Silo Pharma, Inc. Common Stock's Price / Sales is 26.0×, based on as-reported figures from SEC (XBRL) filings.
What is Silo Pharma, Inc. Common Stock's EV / Revenue?
Silo Pharma, Inc. Common Stock's EV / Revenue is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Silo Pharma, Inc. Common Stock's EV / EBITDA?
Silo Pharma, Inc. Common Stock's EV / EBITDA is 0.9×, based on as-reported figures from SEC (XBRL) filings.
What is Silo Pharma, Inc. Common Stock's Revenue (TTM)?
Silo Pharma, Inc. Common Stock's Revenue (TTM) is $72.1K, based on as-reported figures from SEC (XBRL) filings.
What is Silo Pharma, Inc. Common Stock's Net Income (TTM)?
Silo Pharma, Inc. Common Stock's Net Income (TTM) is -$4.8M, based on as-reported figures from SEC (XBRL) filings.
What is Silo Pharma, Inc. Common Stock's EBITDA?
Silo Pharma, Inc. Common Stock's EBITDA is -$4.8M, based on as-reported figures from SEC (XBRL) filings.
What is Silo Pharma, Inc. Common Stock's Diluted EPS (TTM)?
Silo Pharma, Inc. Common Stock's Diluted EPS (TTM) is -3.05, based on as-reported figures from SEC (XBRL) filings.
What is Silo Pharma, Inc. Common Stock's EBITDA Margin?
Silo Pharma, Inc. Common Stock's EBITDA Margin is -6615.5%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · SILOAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
LICENSE FEE REVENUE
YoY growth-100.0%+0.0%+0.0%+0.0%
COST OF REVENUES
GROSS PROFIT (LOSS)
% of revenue—-14.8%-14.8%-14.8%
OPERATING EXPENSES:
Compensation expense
Professional fees
Research and development
Other selling, general and administrative expenses
Total operating expenses
% of revenue—8831.7%4348.5%6373.4%
LOSS FROM OPERATIONS
% of revenue—-8846.4%-4363.3%-6388.2%
OTHER INCOME (EXPENSE):
Interest and dividend income, net
Interest expense
Gain on debt settlement———
Net realized gain on short-term debt investments—
Unrealized gain on short-term tokenized investments funds——
Staking income on crypto assets——
Realized loss on crypto assets———
Unrealized loss on crypto assets, at fair value——
Impairment loss on crypto assets, at cost——
Foreign currency transaction loss——
Total other income, net
LOSS BEFORE PROVISION FOR INCOME TAXES
Provision for income taxes————
NET LOSS
% of revenue—-9137.5%-4890.3%-6160.5%
Net loss
% of revenue—-9137.5%-4890.3%-6160.5%
Basic (in Dollars per share)
Diluted (in Dollars per share)